ArticleHeliyon2024
Enhancing kidney disease prediction with optimized forest and ECG signals data.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ECG-based deep learning for chronic kidney disease detection and cardiovascular risk prediction.BMC medical informatics and decision making · 2025Article
- Artificial intelligence in chronic kidney disease: Bibliometric and visual analysis of trends and future directions.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To improve the early detection of Chronic Kidney Disease (CKD) utilizing electrocardiogram (ECG) data, this study explores the use of the Optimized Forest (Opt-Forest) model. Exploiting the possible relationship between kidney function and ECG data, we investigate Opt-Forest's performance in comparison to popular machine learning (ML) models. We evaluate Opt-Forest and find that it outperforms other options in CKD prediction based on many measures such as classification accuracy (CA), false positive rate (FPR), and true positive rate (TPR). In comparison to previous models, Opt-Forest has superior sensitivity and specificity, with a TPR of 0.787 and a low FPR of 0.174. With an accuracy of 78.68 %, a KS of 0.641, and a low RMSE of 0.174, Opt-Forest also demonstrates robustness in CKD prediction. This study demonstrates the potential of Opt-Forest to improve patient outcomes and medical diagnostics, as well as the usefulness of ECG data in enhancing early CKD diagnosis. Prospective research avenues to advance precision medicine in nephrology involve investigating deep learning methodologies and incorporating patient-specific data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.